A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Apr 29, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how sleep problems can affect the treatment of lung cancer in patients who are receiving a specific type of therapy called immunotherapy. Immunotherapy helps the body's immune system fight cancer, but not all patients respond the same way. Researchers want to understand if having sleep disturbances might influence how well these treatments work for people with non-small cell lung cancer (NSCLC).

To participate in this study, individuals must be at least 18 years old, have a diagnosis of stage II to IV non-small cell lung cancer, and be planning to start immunotherapy. However, those with serious mental health issues, recent chemotherapy or radiation treatment, or other significant health problems may not be eligible. While the study is not yet recruiting participants, those who join will help researchers learn more about the connection between sleep and cancer treatment, which could lead to better care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of non-small-cell lung cancer (stage II-IV) Age 18 and older Immune checkpoint inhibitor therapy (e.g., nivolumab, pembrolizumab, etc.) is planned.
• • Be able to understand the study and provide informed consent
• Exclusion Criteria:
• • Coexisting serious mental illness (e.g., major depression, anxiety, etc.) Recent chemotherapy or radiotherapy Other serious comorbidities (e.g., heart disease, liver and kidney insufficiency)